Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455325 · ClinicalTrials.gov registry record · Phase 2
Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00455325 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 35 participants.
The verdict
NCT00455325, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the short-term effectiveness of chloroquine, a protein-activation medication, at improving metabolic syndrome.
Interventions
- DRUG Placebo Comparator: First Intervention (3 weeks)
- DRUG Active Comparator: Second Intervention (3 weeks)
- DRUG Active Comparator: Third Intervention (3 weeks)
- DRUG Active Comparator: Fourth Intervention (3 weeks)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2004-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455325
The ClinicalTrials.gov registry entry for NCT00455325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Comparator: First Intervention (3 weeks) is the first listed.
NCT00455325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00455325 about?
NCT00455325 is a clinical study titled "Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)". Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes. The purpose of this study is to evaluate the short-term effectiveness of chloroquine, a protein-activation medication, at improving metabolic syndrom...
What is the current status of trial NCT00455325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2004-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00455325?
The interventions under investigation include: Placebo Comparator: First Intervention (3 weeks) (DRUG), Active Comparator: Second Intervention (3 weeks) (DRUG), Active Comparator: Third Intervention (3 weeks) (DRUG), Active Comparator: Fourth Intervention (3 weeks) (DRUG).
Who is sponsoring clinical trial NCT00455325?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.